GlassScriptPhysician profile
Sara Abdelaziz
NPI 1598258089
$389.67
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $301 · 2020: $12.40 · 2021: $76.04.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medicure Pharma INC. | $88.88 | 2019 | |
| Esperion Therapeutics, INC. | $76.04 | 2021 | |
| Janssen Pharmaceuticals, INC | $66.55 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $36.67 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $25.72 | 2019 | |
| Pfizer INC. | $25.44 | 2019 | |
| Lundbeck LLC | $21.19 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.71 | 2019 | |
| Exelixis INC. | $16.68 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.79 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Abdelaziz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.